In the past week, CYTO stock has gone down by -14.85%, with a monthly decline of -28.58% and a quarterly plunge of -55.09%. The volatility ratio for the week is 18.70%, and the volatility levels for the last 30 days are 11.79% for Altamira Therapeutics Ltd The simple moving average for the last 20 days is -14.74% for CYTO’s stock, with a simple moving average of -66.14% for the last 200 days.
Is It Worth Investing in Altamira Therapeutics Ltd (NASDAQ: CYTO) Right Now?
The 36-month beta value for CYTO is also noteworthy at 2.42. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CYTO is 3.76M, and at present, short sellers hold a 0.83% of that float. The average trading volume of CYTO on November 15, 2024 was 362.40K shares.
CYTO) stock’s latest price update
The stock price of Altamira Therapeutics Ltd (NASDAQ: CYTO) has jumped by 3.71 compared to previous close of 0.41. Despite this, the company has seen a fall of -14.85% in its stock price over the last five trading days. zacks.com reported 2024-10-15 that Auris (CYTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
CYTO Trading at -30.76% from the 50-Day Moving Average
After a stumble in the market that brought CYTO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -97.50% of loss for the given period.
Volatility was left at 11.79%, however, over the last 30 days, the volatility rate increased by 18.70%, as shares sank -30.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -53.26% lower at present.
During the last 5 trading sessions, CYTO fell by -14.85%, which changed the moving average for the period of 200-days by -76.76% in comparison to the 20-day moving average, which settled at $0.5043. In addition, Altamira Therapeutics Ltd saw -87.64% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CYTO
The total capital return value is set at -0.87.
Currently, EBITDA for the company is -1.35 million with net debt to EBITDA at 0.38. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.43.
Conclusion
In summary, Altamira Therapeutics Ltd (CYTO) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
